Advancements in Glioma Treatment: How can Clinical Outcomes be Optimized?
Best Practices for the Provider Approach in Treating Patients With IDH-Mutant Diffuse Glioma
Disclaimer: On August 6, 2024, the FDA approved vorasidenib (Voranigo) for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.
Comments 0
Login to view comments.
Click here to Login
